{"eventGroups":[{"deathsNumAffected":30,"deathsNumAtRisk":55,"description":"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.\n\nTRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.\n\nPOST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.\n\nGRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35.","id":"EG000","otherNumAffected":55,"otherNumAtRisk":55,"seriousNumAffected":11,"seriousNumAtRisk":55,"title":"Treatment (Nonmyeloablative HSCT)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Proven or probable invasive fungal infections","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":55}],"term":"Invasive Fungal Infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":34}],"term":"CMV reactivation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":55}],"term":"Recurrent or progressive malignancy"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":55}],"term":"Bacterial infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":55}],"term":"Graft-versus-host disease"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55}],"term":"Secondary myeloid malignancy"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":55}],"term":"Diffuse alveolar hemorrhage"}]}